Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes (Q36198965)

12 August 2017

1 reference

title

Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes (English)

1 reference

12 August 2017

1 reference

Leiter LA

1

1 reference

12 August 2017

publication date

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

22

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

963-972

1 reference

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Assessing the potential for alpha-glucosidase inhibitors in prediabetic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Deteriorating beta-cell function in type 2 diabetes: a long-term model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Insulin secretion in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Molecular insights into insulin action and secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Beta-cell deterioration--prospects for reversal or prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

TNF-alpha and insulin resistance: summary and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Long-term glycaemic control with pioglitazone in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Effect of thiazolidinediones on body weight in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2005.01605.X

10.1111/J.1464-5491.2005.01605.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference